ImmunityBio Files 8-K on Financials

Ticker: IBRX · Form: 8-K · Filed: Apr 15, 2025 · CIK: 1326110

Immunitybio, Inc. 8-K Filing Summary
FieldDetail
CompanyImmunitybio, Inc. (IBRX)
Form Type8-K
Filed DateApr 15, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, sec-filing

Related Tickers: IBIO

TL;DR

IBIO filed an 8-K for financial updates, no specific numbers yet.

AI Summary

ImmunityBio, Inc. filed an 8-K on April 15, 2025, reporting on its financial condition and results of operations. The filing does not contain specific financial figures or operational updates but serves as a notification of these items.

Why It Matters

This filing indicates that ImmunityBio is providing updates on its financial condition and operational results to the SEC, which is standard practice for publicly traded companies.

Risk Assessment

Risk Level: low — This is a routine filing reporting on financial condition and results of operations, not indicating any immediate material changes or risks.

Key Players & Entities

  • ImmunityBio, Inc. (company) — Registrant
  • April 15, 2025 (date) — Date of Report
  • Delaware (jurisdiction) — State of Incorporation
  • 3530 John Hopkins Court (address) — Principal Executive Offices
  • San Diego, California (location) — Principal Executive Offices Location
  • NantKwest, Inc. (company) — Former Company Name
  • Conkwest, Inc. (company) — Former Company Name
  • ZelleRx Corp (company) — Former Company Name

FAQ

What specific financial information is being reported by ImmunityBio, Inc. in this 8-K?

The filing indicates that it pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but specific figures are not detailed within the provided text.

When was this 8-K report filed with the SEC?

The report was filed on April 15, 2025.

What is the principal executive office address for ImmunityBio, Inc.?

The principal executive offices are located at 3530 John Hopkins Court, San Diego, California, 92121.

Has ImmunityBio, Inc. operated under any former names?

Yes, ImmunityBio, Inc. has operated under the former names NantKwest, Inc., Conkwest, Inc., and ZelleRx Corp.

What is the SIC code for ImmunityBio, Inc.?

The Standard Industrial Classification (SIC) code for ImmunityBio, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 15, 2025 regarding ImmunityBio, Inc. (IBRX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.